Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Asset disposition
Acq. announced
Director departure
Appointed director
MEDICINES CO (MDCO) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/06/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/06/2020 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accele...
Docs: "Amended and Restated Certificate of Incorporation of The Medicines Company",
"Amended and Restated Bylaws of The Medicines Company",
"Supplemental Indenture, to the indenture, between the Company and the Trustee",
"Supplemental Indenture, to the indenture, between the Company and the Trustee",
"Supplemental Indenture, to the indenture, between the Company and the Trustee",
"Notice of Redemption",
"The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024 PARSIPPANY, N.J., January 6, 2020 – The Medicines Company today provided notice of a Make-Whole Fundamental Change to holders of its 2.50% Convertible Senior Notes due 2022 , 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024 . The consummation of the previously announced transactions contemplated by the Agreement and Plan of Merger, dated as of November 23, 2019 , by and among the Company, Novartis AG and Medusa Merger Corporation , constitutes a Make-Whole Fundamental Change under: the Indenture, dated as of January 13, 2015, governing th...",
"Fundamental Change Notice to Holders of 2.50% Convertible Senior Notes due 2022",
"Fundamental Change Notice to Holders of 2.75% Convertible Senior Notes due 2023"
11/25/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Agreement and Plan of Merger, by and among The Medicines Company, Novartis AG and Medusa Merger Corporation",
"Media Inquiries Michael Blash Communications +1 973 290 6100",
"Notice to Holders of 2.50% Convertible Senior Notes due 2022",
"Notice to Holders of 2.75% Convertible Senior Notes due 2023",
"Notice to Holders of 3.50% Convertible Senior Notes due 2024"
10/30/2019 8-K Quarterly results
07/24/2019 8-K Quarterly results
Docs: "Investor Relations Krishna Gorti, M.D. Vice President, Investor Relations 973 290 6122"
06/28/2019 8-K Quarterly results
06/05/2019 8-K Submission of Matters to a Vote of Security Holders
04/25/2019 8-K Quarterly results
Docs: "Media Inquiries Michael Blash Vice President, Communications 973 290 6100"
03/18/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/27/2019 8-K Quarterly results
01/14/2019 8-K Asset disposition
01/04/2019 8-K Asset disposition
12/18/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture (including Form of Notes), by and between The Medicines Company and Wells Fargo Bank, National Association, a national banking association, as Trustee"
12/14/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "The Medicines Company Prices $150 Million of Convertible Notes December 13, 2018 9:43 PM Eastern Standard Time"
12/12/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Risk Factors"
12/12/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes December 12, 2018 04:30 PM Eastern Standard Time"
12/11/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT , made this 10 th day of December 2018, is entered into by THE MEDICINES COMPANY, a Delaware corporation with its principal place of business at 8 Sylvan Way, Parsippany, New Jersey 07054 , and MARK TIMNEY . W I T N E S S E T H: WHEREAS, the Company desires to employ the Employee on the terms and subject to the conditions set forth in this Agreement, and the Employee desires to accept such employment. NOW, THEREFORE, for and in consideration of the premises and the mutual promises, covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows: Section 1.Term of Employment. The Company hereby agrees to emp...",
"on the Payment Date, in",
"The Medicines Company Appoints Mark Timney as Chief Executive Officer"
11/08/2018 8-K Quarterly results
Docs: "The Medicines Company Reports Third-Quarter 2018 Results"
08/28/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/01/2018 8-K Quarterly results
Docs: "The Medicines Company Reports Second-Quarter 2018 Results"
06/06/2018 8-K Quarterly results
04/25/2018 8-K Quarterly results
03/27/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/27/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors"
02/26/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/21/2018 8-K Quarterly results
Docs: "The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results"
02/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/11/2018 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics",
"UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION"
01/05/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/04/2017 8-K Entry into a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Other Events, Financial Stateme...
Docs: "PURCHASE AND SALE AGREEMENT dated as of November 28, 2017 by and between THE MEDICINES COMPANY and MELINTA THERAPEUTICS, INC.",
"The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics —Transaction will significantly strengthen the Company’s financial position; expected to provide sufficient cash and liquidity to advance inclisiran through anticipated completion of pivotal trials and data readout in second half of 2019— —Transaction structure will provide potential to create additional value through robust royalty structure on future sales of antibiotic portfolio and ownership of Melinta common stock"
11/15/2017 8-K Appointed a new director
Docs: "Amendment to the Second Amended and Restated Bylaws of the Company, approved, adopted and effective as of November 13, 2017",
"The Medicines Company names Dr. Fred Eshelman as Executive Chairman; appoints Geno Germano to its Board of Directors"
10/25/2017 8-K Quarterly results
08/09/2017 8-K Quarterly results
Docs: "The Medicines Company Reports Second Quarter 2017 Business and Financial Results"
06/02/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy